Logo image of IFRX

INFLARX NV (IFRX) Stock Fundamental Analysis

NASDAQ:IFRX - Nasdaq - NL0012661870 - Common Stock - Currency: USD

1.82  -0.03 (-1.62%)

Premarket: 0.93 -0.89 (-48.9%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IFRX. IFRX was compared to 560 industry peers in the Biotechnology industry. IFRX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, IFRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IFRX had negative earnings in the past year.
IFRX had a negative operating cash flow in the past year.
In the past 5 years IFRX always reported negative net income.
In the past 5 years IFRX always reported negative operating cash flow.
IFRX Yearly Net Income VS EBIT VS OCF VS FCFIFRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -51.40%, IFRX perfoms like the industry average, outperforming 47.32% of the companies in the same industry.
IFRX has a Return On Equity (-63.47%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -51.4%
ROE -63.47%
ROIC N/A
ROA(3y)-41.63%
ROA(5y)-39.97%
ROE(3y)-49.99%
ROE(5y)-47.39%
ROIC(3y)N/A
ROIC(5y)N/A
IFRX Yearly ROA, ROE, ROICIFRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

IFRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IFRX Yearly Profit, Operating, Gross MarginsIFRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

3

2. Health

2.1 Basic Checks

IFRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IFRX has been increased compared to 1 year ago.
The number of shares outstanding for IFRX has been increased compared to 5 years ago.
IFRX has a worse debt/assets ratio than last year.
IFRX Yearly Shares OutstandingIFRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
IFRX Yearly Total Debt VS Total AssetsIFRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

IFRX has an Altman-Z score of -1.90. This is a bad value and indicates that IFRX is not financially healthy and even has some risk of bankruptcy.
IFRX has a Altman-Z score (-1.90) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.00 indicates that IFRX is not too dependend on debt financing.
IFRX has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.9
ROIC/WACCN/A
WACC7.1%
IFRX Yearly LT Debt VS Equity VS FCFIFRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 5.28 indicates that IFRX has no problem at all paying its short term obligations.
The Current ratio of IFRX (5.28) is comparable to the rest of the industry.
A Quick Ratio of 4.86 indicates that IFRX has no problem at all paying its short term obligations.
IFRX has a Quick ratio (4.86) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.28
Quick Ratio 4.86
IFRX Yearly Current Assets VS Current LiabilitesIFRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for IFRX have decreased by -5.63% in the last year.
Looking at the last year, IFRX shows a very strong growth in Revenue. The Revenue has grown by 31.38%.
EPS 1Y (TTM)-5.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
Revenue 1Y (TTM)31.38%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 31.33% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 222.50% on average over the next years. This is a very strong growth
EPS Next Y0.37%
EPS Next 2Y3.46%
EPS Next 3Y12.46%
EPS Next 5Y31.33%
Revenue Next Year-45.24%
Revenue Next 2Y4.81%
Revenue Next 3Y484.87%
Revenue Next 5Y222.5%

3.3 Evolution

IFRX Yearly Revenue VS EstimatesIFRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
IFRX Yearly EPS VS EstimatesIFRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IFRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IFRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IFRX Price Earnings VS Forward Price EarningsIFRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IFRX Per share dataIFRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

IFRX's earnings are expected to grow with 12.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.46%
EPS Next 3Y12.46%

More info and screens

0

5. Dividend

5.1 Amount

IFRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INFLARX NV

NASDAQ:IFRX (5/27/2025, 8:00:01 PM)

Premarket: 0.93 -0.89 (-48.9%)

1.82

-0.03 (-1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners22.29%
Inst Owner Change33.07%
Ins Owners7.33%
Ins Owner ChangeN/A
Market Cap122.18M
Analysts84.62
Price Target9.52 (423.08%)
Short Float %1.8%
Short Ratio3.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49.68%
Min EPS beat(2)30.73%
Max EPS beat(2)68.63%
EPS beat(4)2
Avg EPS beat(4)15.64%
Min EPS beat(4)-19.14%
Max EPS beat(4)68.63%
EPS beat(8)5
Avg EPS beat(8)18.13%
EPS beat(12)9
Avg EPS beat(12)27.72%
EPS beat(16)11
Avg EPS beat(16)15.54%
Revenue beat(2)0
Avg Revenue beat(2)-100.43%
Min Revenue beat(2)-100.86%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-61.15%
Min Revenue beat(4)-100.86%
Max Revenue beat(4)48.71%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.45%
PT rev (3m)8.53%
EPS NQ rev (1m)-34.19%
EPS NQ rev (3m)18.43%
EPS NY rev (1m)-19.08%
EPS NY rev (3m)21.26%
Revenue NQ rev (1m)-1.1%
Revenue NQ rev (3m)-31.02%
Revenue NY rev (1m)-50%
Revenue NY rev (3m)-78.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 826.33
P/FCF N/A
P/OCF N/A
P/B 1.53
P/tB 1.53
EV/EBITDA N/A
EPS(TTM)-0.85
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0
BVpS1.19
TBVpS1.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.4%
ROE -63.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41.63%
ROA(5y)-39.97%
ROE(3y)-49.99%
ROE(5y)-47.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.68%
Cap/Sales 31.64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.28
Quick Ratio 4.86
Altman-Z -1.9
F-Score2
WACC7.1%
ROIC/WACCN/A
Cap/Depr(3y)17.06%
Cap/Depr(5y)14.01%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
EPS Next Y0.37%
EPS Next 2Y3.46%
EPS Next 3Y12.46%
EPS Next 5Y31.33%
Revenue 1Y (TTM)31.38%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-45.24%
Revenue Next 2Y4.81%
Revenue Next 3Y484.87%
Revenue Next 5Y222.5%
EBIT growth 1Y-14.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year97.98%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-51.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.92%
OCF growth 3YN/A
OCF growth 5YN/A